ADA Human

Adenosine Deaminase Human Recombinant
Shipped with Ice Packs
In Stock

Description

ADA Human Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 383 amino acids (1-363) and having a molecular mass of 42.9 kDa.
The ADA is fused to a 20 amino acid His-Tag at N-terminus and purified by proprietary chromatographic techniques.

Product Specs

Introduction
Adenosine Deaminase (ADA) is an enzyme that plays a crucial role in the breakdown of adenosine and deoxyadenosine, molecules involved in purine metabolism and adenosine regulation. ADA is essential for proper immune function, particularly in T-cell activation, by interacting with DPP4, a protein influencing cell adhesion.
Description
This product consists of the recombinant human ADA enzyme, produced in E. coli bacteria. It is engineered as a single polypeptide chain without glycosylation, containing 383 amino acids (including a 20 amino acid His-Tag at the N-terminus) and possessing a molecular weight of 42.9 kDa. Purification is achieved using proprietary chromatographic methods.
Physical Appearance
The ADA protein is provided as a clear solution that has undergone sterile filtration.
Formulation
The ADA protein is provided at a concentration of 0.5 mg/ml in a buffer solution containing 20mM Tris-HCL (pH 8), 1mM DTT, and 20% Glycerol.
Stability
For short-term storage (up to 4 weeks), the product can be stored at 4°C. For extended storage, freezing at -20°C is recommended. The addition of a carrier protein (0.1% HSA or BSA) is advised for long-term storage to maintain stability. Minimize repeated freeze-thaw cycles to prevent protein degradation.
Purity
Analysis by SDS-PAGE indicates a purity level exceeding 85%.
Biological Activity
The specific activity of the enzyme is determined to be greater than 25 units/mg. This activity level has been confirmed through enzymatic assays measuring the conversion rate of adenosine to inosine at standard conditions (pH 7.5, 25°C).
Synonyms
Adenosine deaminase, Adenosine aminohydrolase, ADA1, EC 3.5.4.4.
Source
Escherichia Coli.
Amino Acid Sequence
MGSSHHHHHH SSGLVPRGSH MAQTPAFDKP KVELHVHLDG SIKPETILYY GRRRGIALPA NTAEGLLNVI GMDKPLTLPD FLAKFDYYMP AIAGCREAIK RIAYEFVEMK AKEGVVYVEV RYSPHLLANS KVEPIPWNQA EGDLTPDEVV ALVGQGLQEG ERDFGVKARS ILCCMRHQPN WSPKVVELCK KYQQQTVVAI DLAGDETIPG SSLLPGHVQA YQEAVKSGIH RTVHAGEVGS AEVVKEAVDI LKTERLGHGY HTLEDQALYN RLRQENMHFE ICPWSSYLTG AWKPDTEHAV IRLKNDQANY SLNTDDPLIF KSTLDTDYQM TKRDMGFTEE EFKRLNINAA KSSFLPEDEK RELLDLLYKA YGMPPSASAG QNL

Q&A

What are the different meanings of "ADA" relevant to human research?

ADA has several distinct meanings in human research contexts, each requiring different methodological approaches:

  • Adenosine Deaminases (ADA1 and ADA2): Enzymes involved in purine metabolism with significant implications for immune function. Research typically involves biochemical assays, binding studies, and clinical correlations .

  • Americans with Disabilities Act (ADA): Legislation providing civil rights protections to individuals with disabilities, affecting research design, participant recruitment, and accessibility considerations .

  • Adult Development and Aging (ADA): A research field examining developmental processes across adulthood using longitudinal methodologies, cognitive assessments, and social metrics .

  • Algorithms, Data, and Artificial Intelligence (ADA): An emerging framework addressing ethical implications of computational methods in human research contexts .

  • ADA Principles in Clinical Research: Guidelines ensuring inclusivity and accessibility in human subjects research .

When designing research protocols, investigators must clearly specify which ADA context they're operating within and apply the appropriate methodological frameworks accordingly.

How do researchers determine which ADA regulatory frameworks apply to their specific human studies?

Determining applicable ADA frameworks requires a systematic evaluation approach:

  • Identify research domain: First categorize your research (biomedical, clinical trial, behavioral, technological intervention)

  • Assess participant characteristics: Determine if your study involves protected populations under ADA legislation

  • Review institutional policies: Consult with IRB regarding ADA compliance requirements specific to your institution

  • Conduct regulatory gap analysis: Compare study protocols against relevant ADA frameworks

  • Document compliance strategy: Develop and maintain records of how your research addresses applicable ADA requirements

For clinical research specifically, researchers should conduct accessibility audits and implement robust accessibility features in research platforms to ensure compliance with ADA principles .

What theoretical frameworks guide current ADA research in human development studies?

Contemporary ADA research employs multiple theoretical frameworks, with methodological implications for each:

  • Life-span developmental theories: Requires longitudinal study designs with repeated measures across significant time periods

  • Cognitive neuroscience approaches: Utilizes neuroimaging methods combined with cognitive testing

  • Family systems perspectives: Employs multi-level analysis examining both individual and family unit data

  • Health and wellness frameworks: Integrates biometric data with self-reported measures

These frameworks are not mutually exclusive; advanced ADA research often triangulates findings across multiple theoretical approaches. Published ADA research appears in top-tier journals including Journal of Gerontology: Psychological Sciences, Journal of Gerontology: Social Sciences, The Gerontologist, and Journal of Marriage and Family .

How should researchers design studies to effectively examine both individual and family-level variables in adult development research?

Methodologically sound ADA research addressing both individual and family dynamics requires:

  • Multi-level sampling strategy: Recruit both individuals and complete family units using stratified sampling techniques

  • Mixed-methods data collection: Combine quantitative instruments (standardized assessments, surveys) with qualitative approaches (interviews, observation)

  • Hierarchical analytical approach: Employ statistical methods that account for nested data (individuals within families)

  • Longitudinal design elements: Track developmental trajectories and family relationship changes over time

  • Cross-contextual measures: Assess both home and community-based interactions

Research centers like the Engagement Center for Creative Aging and the Center for Gerontology provide infrastructural support for such complex study designs, offering opportunities for methodological innovation in addressing these multi-level research questions .

What constitutes a "major life activity" under ADA definitions, and how does this impact research participant classification?

The ADA provides a non-exhaustive list of major life activities that researchers must consider when designing inclusion criteria and accessibility measures:

  • Self-care activities: Caring for oneself, performing manual tasks

  • Sensory functions: Seeing, hearing

  • Basic physical activities: Eating, sleeping, walking, standing, sitting, reaching, lifting, bending

  • Communication functions: Speaking, reading, communicating, interacting with others

  • Cognitive processes: Learning, concentrating, thinking

  • Working functions: Job-related activities

  • Physiological functions: Immune system operation, normal cell growth, digestive processes, neurological function, respiratory function, circulatory function, etc.

When designing research protocols, investigators must consider how their methodologies might need adaptation to accommodate participants with limitations in these areas. This extends beyond physical accessibility to include accommodations for cognitive processing, sensory limitations, and communication differences.

What methodological adaptations are necessary when conducting human subjects research with participants protected under ADA legislation?

Methodologically rigorous research involving participants with disabilities requires systematic adaptations:

  • Recruitment protocol modifications: Develop alternative formats for consent materials (audio, large print, simplified language)

  • Assessment instrument validation: Ensure psychometric properties remain valid when administered with accommodations

  • Environmental accessibility analysis: Evaluate physical and sensory barriers in research settings

  • Response time flexibility: Adjust protocols to accommodate varying processing speeds

  • Alternative data collection methods: Implement multimodal options for participant responses

  • Statistical analysis considerations: Account for accommodation variables in analysis to prevent confounding

Importantly, research protocols must distinguish between inquiries about disability that are permissible for scientific objectives versus those that might constitute discrimination. Pre-screening questions must focus on ability to perform research tasks rather than disability status itself .

How do ADA1 and ADA2 enzymes differ in their binding properties to human immune cells?

ADA1 and ADA2 demonstrate distinct binding patterns to human immune cells, with important methodological implications for research:

EnzymePrimary Binding CellsReceptor InteractionMethodological Detection
ADA1Lymphocytes expressing CD26, CD16- monocytesBinds CD26 receptorBiotinylated ADA1 with streptavidin-fluorochrome detection
ADA2Neutrophils, monocytes, NK cells, B cellsDoes not bind CD26Cell-specific binding assays

Research findings indicate that ADA1 binding to monocytes inversely correlates with CD16 expression, with CD16- monocytes showing significantly higher ADA1 binding capacity. This suggests differential regulatory roles for these enzymes in various immune cell populations .

Cross-species research demonstrates that mouse ADA1, unlike human ADA1, does not interact with CD26 receptor, but both mouse and human ADA1 bind to a highly conserved receptor on THP1 cells in a mutually exclusive manner .

What are the advanced methodological approaches for investigating ADA enzyme functions in human immunological disorders?

Advanced ADA research methodologies include:

  • Recombinant protein expression systems: Utilize HEK-293T cells for expressing functional human and mouse ADA proteins

  • Binding characterization through flow cytometry: Employ biotinylated ADA with streptavidin-conjugated fluorochromes

  • Competitive binding assays: Use unmodified enzymes to demonstrate binding specificity

  • Subset analysis of immune populations: Correlate ADA binding with cellular surface markers to identify specific binding patterns

  • Cross-species comparative approaches: Compare binding properties between mouse and human ADA to elucidate evolutionary conservation of receptor interactions

These methodologies have revealed that ADA1 and ADA2 target different monocyte subsets, suggesting distinct roles in immune regulation. Further investigation of these binding properties may illuminate pathophysiological mechanisms in autoimmune disorders and immunodeficiencies associated with ADA dysfunction .

How should researchers address the tensions between algorithmic accuracy and fairness in human-centered ADA research?

The ethical implementation of Algorithms, Data, and AI (ADA) in human research requires systematic approaches to reconciling competing values:

  • Methodological transparency: Document algorithm development processes including training data selection criteria and validation methods

  • Fairness metric selection: Clearly define which fairness concepts (group fairness, individual fairness, etc.) are prioritized and why

  • Stakeholder engagement protocols: Implement structured processes for incorporating diverse perspectives in algorithm development

  • Counterfactual testing: Develop formal methods to assess how algorithms would perform across different demographic groups

  • Trade-off analysis framework: Quantify the relationships between accuracy improvements and fairness impacts

Researchers must explicitly address tensions between: (i) using algorithms to improve decision accuracy versus ensuring fair and equal treatment, (ii) benefits of personalization versus solidarity and citizenship values, and (iii) data utility versus privacy and informational autonomy .

What methodological approaches help researchers identify when ADA technologies disproportionately impact specific human populations?

Rigorous assessment of differential impacts requires:

  • Intersectional audit methodology: Systematically evaluate outcomes across overlapping demographic categories (gender, class, disability status, ethnicity)

  • Temporal impact assessment: Distinguish between short-term benefits and longer-term consequences of ADA implementations

  • Multi-level analysis: Examine how individual benefits might create collective problems

  • Evidence-based impact evaluation: Build stronger evidence base on current use and impacts of ADA technologies across different sectors and demographics

Research should prioritize identifying impacts on underrepresented groups, particularly women and people of color in relevant sectors. This requires deliberate sampling strategies and analytical frameworks designed to detect disparate effects that might otherwise remain invisible in aggregate analyses .

What are the essential components of an effective ADA compliance audit for human clinical research protocols?

A comprehensive ADA compliance audit for clinical research should systematically assess:

  • Physical accessibility: Evaluate research facilities for compliance with dimensional requirements, including entrance widths, clear floor space, and reach ranges

  • Digital accessibility: Review electronic consent forms, surveys, and research interfaces using WCAG 2.1 guidelines

  • Communication accessibility: Assess availability of auxiliary aids and services for participants with sensory impairments

  • Procedural accessibility: Examine flexibility in research protocols to accommodate various disabilities

  • Staff competency: Evaluate personnel training on disability etiquette and accommodation procedures

Documentation of audit findings, remediation plans, and implementation timelines is essential for demonstrating good-faith efforts toward compliance. Regular re-auditing ensures sustained accessibility as research protocols evolve .

How can researchers implement robust accessibility features in clinical research platforms while maintaining methodological rigor?

Maintaining methodological integrity while enhancing accessibility requires:

  • Universal design approach: Design research instruments from the outset to be usable by the widest possible range of participants

  • Equivalence testing: Validate that accessible alternatives provide comparable data quality to standard methods

  • Adaptive protocol implementation: Develop branching methodologies that adjust to participant capabilities while collecting comparable data

  • Multimodal data collection: Implement multiple formats for gathering the same information to accommodate different abilities

  • Accessibility metadata: Track and analyze which accessibility features were utilized to identify potential confounding variables

These approaches should be documented in research protocols and approved by IRBs to ensure that accessibility accommodations do not compromise scientific validity or introduce uncontrolled variables into the research design .

Product Science Overview

Introduction

Adenosine Deaminase (ADA), also known as adenosine aminohydrolase, is a crucial enzyme involved in the purine nucleotide catabolism pathway. It catalyzes the hydrolytic deamination of adenosine and deoxyadenosine to inosine and deoxyinosine, respectively . This enzyme is expressed in virtually all tissues, with particularly high levels in T-lymphocytes .

Structure and Function

The human ADA enzyme is a monomeric protein with a molecular weight of approximately 40-42 kDa . The enzyme’s structure consists of 362 amino acids, excluding the initiator methionine . ADA belongs to the α/β class of proteins, characterized by a mixed α-helix and β-sheet structure .

ADA plays a pivotal role in maintaining the balance of purine nucleotides within the cell. By converting adenosine to inosine, ADA helps regulate the levels of adenosine, which can have various physiological effects, including modulation of the immune response .

Recombinant ADA

Recombinant human ADA (rhADA) is produced using baculovirus expression systems in insect cells, such as Spodoptera frugiperda (Sf21) . The recombinant protein is often tagged with a histidine tag to facilitate purification and is supplied in a carrier-free formulation to avoid interference from other proteins .

Clinical Significance

ADA deficiency is a well-known cause of severe combined immunodeficiency (SCID), an autosomal recessive disorder characterized by a lack of functional T and B lymphocytes . Patients with ADA-SCID have undetectable levels of ADA activity, leading to the accumulation of toxic metabolites that impair lymphocyte development and function .

Recombinant ADA has been used as an enzyme replacement therapy for patients with ADA-SCID. This therapy involves the administration of polyethylene glycol (PEG)-modified ADA (PEG-ADA) to reduce the immunogenicity and prolong the half-life of the enzyme in the bloodstream .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.